O. Rixe

632 total citations
16 papers, 482 citations indexed

About

O. Rixe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, O. Rixe has authored 16 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Reproductive Medicine. Recurrent topics in O. Rixe's work include HER2/EGFR in Cancer Research (4 papers), Cancer Treatment and Pharmacology (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). O. Rixe is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Cancer Treatment and Pharmacology (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). O. Rixe collaborates with scholars based in France, United States and China. O. Rixe's co-authors include James J. Driscoll, M. Riofrio, Karim Fizazi, A. Le Cesne, M. Spielmann, J.P. Delord, Laurent Zelek, Gonzalo Rubio, Alexey Manikhas and Binghe Xu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

O. Rixe

15 papers receiving 472 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Rixe France 8 355 170 128 89 47 16 482
Ragene Rivera United States 10 473 1.3× 197 1.2× 142 1.1× 90 1.0× 29 0.6× 13 573
D. Ilegbodu United States 12 574 1.6× 162 1.0× 181 1.4× 105 1.2× 33 0.7× 30 711
Rubi K. Li Philippines 8 575 1.6× 192 1.1× 112 0.9× 64 0.7× 64 1.4× 9 666
Jin‐Hee Ahn South Korea 15 522 1.5× 143 0.8× 86 0.7× 97 1.1× 44 0.9× 29 718
Patricia Tresca France 13 350 1.0× 127 0.7× 190 1.5× 141 1.6× 22 0.5× 26 542
Kathryn Clarke United States 4 488 1.4× 147 0.9× 86 0.7× 88 1.0× 45 1.0× 5 568
Valorie F. Chan United States 7 653 1.8× 225 1.3× 318 2.5× 140 1.6× 68 1.4× 10 796
P. Ravdin United States 6 392 1.1× 220 1.3× 46 0.4× 92 1.0× 61 1.3× 7 515
Herb Kotz United States 11 325 0.9× 86 0.5× 130 1.0× 148 1.7× 33 0.7× 23 494
K Hisamatsu Japan 12 229 0.6× 168 1.0× 74 0.6× 56 0.6× 31 0.7× 35 361

Countries citing papers authored by O. Rixe

Since Specialization
Citations

This map shows the geographic impact of O. Rixe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Rixe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Rixe more than expected).

Fields of papers citing papers by O. Rixe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Rixe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Rixe. The network helps show where O. Rixe may publish in the future.

Co-authorship network of co-authors of O. Rixe

This figure shows the co-authorship network connecting the top 25 collaborators of O. Rixe. A scholar is included among the top collaborators of O. Rixe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Rixe. O. Rixe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Tan, Zongqing, Pingping Chen, S. E. Glover, et al.. (2012). Abstract 5713: Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-Trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Cancer Research. 72(8_Supplement). 5713–5713. 1 indexed citations
2.
Sparano, Joseph A., Eduard Vrdoljak, O. Rixe, et al.. (2010). Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology. 28(20). 3256–3263. 175 indexed citations
3.
Driscoll, James J. & O. Rixe. (2009). Overall Survival: Still the Gold Standard. The Cancer Journal. 15(5). 401–405. 109 indexed citations
4.
5.
Billemont, Bertrand, et al.. (2008). PERIOPERATIVE USE AND SURGICAL COMPLICATIONS OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA. European Urology Supplements. 7(3). 306–306. 7 indexed citations
6.
Motzer, Robert J., M. Dror Michaelson, Thomas E. Hutson, et al.. (2007). 4509 POSTER Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. European Journal of Cancer Supplements. 5(4). 301–301. 15 indexed citations
7.
Paridaens, Robert, et al.. (2007). Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1058–1058. 12 indexed citations
8.
Pautier, Patricia, F. Joly, Pierre Kerbrat, et al.. (2007). Gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: Final results of a phase II study. Journal of Clinical Oncology. 25(18_suppl). 5566–5566. 1 indexed citations
9.
Huong, D. Lê Thi, et al.. (2006). Métastase choroïdienne révélatrice d'un adénocarcinome bronchique. La Revue de Médecine Interne. 27(9). 699–701. 1 indexed citations
10.
Rixe, O., Chris Verslype, Sabine Tejpar, et al.. (2006). Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 13161–13161. 12 indexed citations
11.
Spano, Jean‐Philippe, Christine Lagorce, Robert Benamouzig, et al.. (2005). EGFR and phospho-EGFR expression in colorectal cancer patients and impact on survival. Journal of Clinical Oncology. 23(16_suppl). 3690–3690.
12.
Deplanque, G., A Goupil, Michel Fabbro, et al.. (2004). Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): Preliminary results. Journal of Clinical Oncology. 22(14_suppl). 5075–5075. 5 indexed citations
13.
Zelek, Laurent, M. Riofrio, Karim Fizazi, et al.. (2001). Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 92(9). 2267–2272. 122 indexed citations
14.
Viens, Patrice, Philippe Bougnoux, O. Rixe, et al.. (2001). A phase II trial of a paclitaxel and oxaliplatin combination in advanced ovarian cancer patients pretreated with cisplatin or carboplatin ± taxanes: Preliminary results. European Journal of Cancer. 37. S323–S323. 2 indexed citations
15.
Coeffic, David, A. Benhammouda, O. Rixe, et al.. (1997). Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.. PubMed. 24(1 Suppl 2). S2–38. 4 indexed citations
16.
Weil, M, Christian Borel, O. Rixe, et al.. (1995). [Adjuvant therapy of surgically removed stage I melanoma].. PubMed. 122(5). 315–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ragene Rivera Breakdown of academic impact, for papers by D. Ilegbodu Breakdown of academic impact, for papers by Rubi K. Li Breakdown of academic impact, for papers by Jin‐Hee Ahn Breakdown of academic impact, for papers by Patricia Tresca Breakdown of academic impact, for papers by Kathryn Clarke Breakdown of academic impact, for papers by Valorie F. Chan Breakdown of academic impact, for papers by P. Ravdin Breakdown of academic impact, for papers by Herb Kotz Breakdown of academic impact, for papers by K Hisamatsu
Rankless by CCL
2026